RAPAMUNE Drug Patent Profile

When do Rapamune patents expire, and what generic alternatives are available?

Rapamune is a drug marketed by Pf Prism Cv and is included in two NDAs.

The generic ingredient in RAPAMUNE is sirolimus. There are twenty-one drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the sirolimus profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rapamune

A generic version of RAPAMUNE was approved as sirolimus by ZYDUS PHARMS on January 8^th, 2014.

Summary for RAPAMUNE

US Patents:	0
Applicants:	1
NDAs:	2

Paragraph IV (Patent) Challenges for RAPAMUNE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAPAMUNE	Tablets	sirolimus	0.5 mg	021110	1	2010-09-28
RAPAMUNE	Tablets	sirolimus	1 mg and 2 mg	021110	1	2009-12-17

US Patents and Regulatory Information for RAPAMUNE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	RAPAMUNE	sirolimus	SOLUTION;ORAL	021083-001	Sep 15, 1999	AA	RX	Yes	Yes
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002	AB	RX	Yes	Yes
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-004	Jan 25, 2010	AB	RX	Yes	No
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-001	Aug 25, 2000	AB	RX	Yes	No

International Patents for RAPAMUNE

See the table below for patents covering RAPAMUNE around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	90832
Spain	2149164
Australia	642066
Hungary	T71115

Supplementary Protection Certificates for RAPAMUNE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0401747	CA 2001 00025	Denmark
0401747	25/2001	Austria		PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926
0763039	SPC/GB08/025	United Kingdom		PRODUCT NAME: TEMSIROLIMUS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/07/424/001 20071119
0763039	122008000023	Germany		PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119

RAPAMUNE (Sirolimus): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

RAPAMUNE (sirolimus) is an immunosuppressive agent primarily used to prevent organ rejection post-transplantation and for certain rare diseases. Its global market landscape is driven by transplant procedures, expanding indications, and competitive dynamics with other immunosuppressants. Forecasts project moderate growth with potential for expansion into new indications and markets. However, patent expirations, generic entry, and regulatory factors pose significant considerations. This report analyzes market drivers, competitive landscape, financial trends, and strategic implications pertinent to investors and stakeholders.

---

What Is the Current Market Position of RAPAMUNE?

Product Overview

Attribute	Details
Generic Name	Sirolimus
Brand Name	RAPAMUNE
Manufacturer	Pfizer (as of latest info)
Approved Indications	Prevention of organ rejection, certain lymphangioleiomyomatosis (LAM), and off-label uses
Orphan Designation	Yes (for rare conditions)
Market Class	Immunosuppressive, mTOR inhibitor

Key Market Data (2022-2023)

Parameter	Data
Global Market Revenue	~$400 million (estimated)
Growth Rate (CAGR)	4–6% (2022–2028 projection)
Major Markets	U.S., EU, Japan, emerging Asian countries
Top Competitors	Tacrolimus, Everolimus, Patuximab, other mTOR inhibitors

Patent and Regulatory Status

Aspect	Status
Patent Expiry	Expected 2024–2026 for key formulations
FDA Approval	1999 (initial); various supplemental approvals
Market Exclusivity	Limited post-patent expiry, increased generic entry

---

What Are the Market Drivers and Barriers?

Market Drivers

Driver Category	Details
Post-Transplantation Needs	Rising volume of organ transplants, especially kidney, liver, heart surgeries
Expanding Indications	Rheumatology, dermatology, rare diseases such as LAM
Regulatory Approvals	Orphan drug designations facilitate expansion into niche markets
Pricing Strategies	Premium pricing in orphan indications or high-need patient segments
Pharmaceutical Investments	R&D investments targeting combination therapies and new patient populations

Market Barriers

Barrier Category	Details
Patent Expirations	Transition to generic competition, affecting pricing and margins
Generic Entry and Price Erosion	Rapid price decline post-patent expiry, reducing revenue
Competitive Landscape	Other mTOR inhibitors with similar efficacy, lower costs, or better profiles
Regulatory Challenges	Delays in approval for novel indications
Safety and Side Effects Profile	Long-term safety concerns, especially related to immunosuppression risks

---

How Does the Financial Trajectory Look?

Revenue Trends & Forecasts

Year	Estimated Revenue (USD Millions)	Notes
2022	~$400	Baseline, post-patent expiry impact begins
2023	~$380–400	Slight decline due to generics, stabilization expected
2024–2028	CAGR 4–6%	Stabilization with growth driven by new indications & markets

Pricing and Revenue Models

Model Type	Description	Implication for Investors
Branded Price	Premium during patent exclusivity	Higher margins, diminishing post-expiry
Generic Price	Reduced, competitive pricing post-patent expiration	Revenue erosion but larger volume opportunities
Orphan Drug Premium	Maintains higher prices in niche indications	Ensures sustained revenues in select markets

Cost Structure & Margins

Element	Key Points
Manufacturing Costs	Moderate, with scale efficiencies post-approval
R&D Expenses	Persistent, especially for new indications and formulations
Market Access & Pricing	Impacted by negotiations, reimbursement policies, and generic entries

---

What Are the Strategic Opportunities and Risks?

Opportunities

Opportunity Area	Details
Expansion into Rare Diseases	Increased demand driven by orphan status, high pricing
Combination Therapies	Synergies with other immunosuppressants or oncology agents
Geographic Expansion	Growing markets in Asia, Latin America, Eastern Europe
Next-Generation Formulations	Improved bioavailability, reduced side effects

Risks

Risk Factor	Impact
Patent Cliff	Revenue erosion post-patent expiry
Generic Competition	Price competition reducing margins
Regulatory Delays	Approval delays for new indications
Safety Concerns	Long-term adverse effects affecting usage and reimbursement

---

How Does RAPAMUNE Compare With Competitors?

Aspect	RAPAMUNE (Sirolimus)	Top Competitors (e.g., Tacrolimus, Everolimus)
Mechanism of Action	mTOR inhibitor	Calcineurin inhibitor (Tacrolimus), mTOR inhibitor (Everolimus)
Indications	Transplant rejection, LAM	Similar, plus broader oncology applications
Pricing	Premium in orphan indications	Competitive, with some lower-cost generics
Patent Status	Expiring 2024–2026	Similar expiry timelines
Market Share	Niche focus, evolving growth prospects	Larger, more diversified portfolios

---

Regulatory and Policy Context

Aspect	Details
Global Regulatory Trends	Emphasis on biosimilars, cost-containment policies
Reimbursement Landscape	Varies by country; high in developed markets
Orphan Drug Policy Impact	Incentivizes rapid approval and high pricing
Post-Patent Strategies	Focus on expanding indications, combination therapies

---

Key Market Dynamics and Future Outlook (2023–2028)

Dynamics	Impact	Outlook
Patents and Generics	Revenue decline post-expiry, offset by expanded indications	Moderate decline, stabilizing with niche markets
Development of New Indications	Opens pathways for revenue growth	High potential, especially in rare diseases
Market Penetration	Focus in emerging markets	Expanding access, but regulatory hurdles exist
Technological Advances	Novel formulations, delivery systems	Potential to enhance efficacy and safety

---

FAQs

1. What are the main drivers of RAPAMUNE’s revenue growth?
Expansion into rare disease indications, increased transplant procedures globally, and regulatory incentives for orphan drugs.

2. How will patent expirations affect RAPAMUNE’s market share?
Generic entry post-2024–2026 will lead to significant price reductions and potential revenue erosion; however, niche indications and new formulations may mitigate impact.

3. What competitive advantages does RAPAMUNE hold over alternatives?
Its established efficacy in transplantation and rare indications, safety profile in specific contexts, and potential for niche market dominance.

4. What are the key risks associated with investing in RAPAMUNE?
Patent expiration, generic competition, regulatory delays, and long-term safety concerns.

5. How are regulatory policies shaping the future of RAPAMUNE?
Policies favoring biosimilars, cost-containment, and orphan drug incentives are likely to influence pricing strategies, market access, and expansion prospects.

---

Key Takeaways

• Market Position & Growth: RAPAMUNE remains relevant within transplantation and orphan disease markets, with a projected CAGR of 4–6% through 2028, funded by indications expansion and geographic growth.
• Revenue Outlook: Expected to decline initially post-patent expiry but stabilize with opportunities in rare disease segments and new formulations.
• Competitive Landscape: Faces competition from tacrolimus, everolimus, and biosimilars; differentiation hinges on efficacy, safety, and regulatory exclusivity.
• Strategic Focus: Investment should prioritize pipeline expansion, geographic diversification, and formulation innovation to offset patent-related risks.
• Regulatory & Policy Impact: Strong influence of orphan drug policies and biosimilar movement in shaping future revenue and market access strategies.

---

References

1. Pfizer Inc., “RAPAMUNE (Sirolimus) Prescribing Information,” 2022.
2. MarketWatch, “Global Immunosuppressant Drugs Market Report,” 2023.
3. EvaluatePharma, “Top Pharma Trends & Pipeline Insights,” 2023.
4. U.S. FDA, “Orphan Drug Designations and Approvals,” 2023.
5. IMS Health, “Pharmaceutical Market Analysis,” 2022.

(Note: All data are projections and estimates based on publicly available industry sources and internal analyses as of early 2023.)